General
Preferred name
PERPHENAZINE
Synonyms
Prednazate ()
Perphenazine (D8 Dihydrochloride) ()
Perphenazin ()
Etaperazine ()
Trilafon ()
Perphenazin, Trilafon, Etaperazine ()
Perphenazine dihydrochloride ()
PERFENAZINA ()
FENTAZIN ()
Chlorpiprazine ()
Trilafon-LA ()
Decentan ()
NSC-150866 ()
Perphenazine component of etrafon-a ()
PERPHENAZINE MALEATE ()
PERPHENAZINE COMPONENT OF ETRAFON-A ()
Perphenazine-d4 ()
P&D ID
PD000799
CAS
58-39-9
130-69-8
2015-28-3
155593-75-2
Tags
available
drug
Approved by
FDA
First approval
1957
Drug indication
Schizophrenia
Psychosis
Drug Status
approved
Max Phase
4.0
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION Perphenazine is a typical antipsychotic drug, acting principally as a dopamine D2 receptor antagonist. (GtoPdb)
PRICE 29
DESCRIPTION Perphenazine is an orally active dopamine receptor and histamine-1 receptor antagonist, with Ki values of 0.56 nM (D2), 0.43 nM (D3), 6 nM (5-HT2A), respectively. Perphenazine also binds to Alpha-1A adrenergic receptor. Perphenazine inhibits cancer cell proliferation, and induces apoptosis. Perphenazine can be used in the research of mental disease, cancer, inflammation[1][3][5].
PRICE 962
DESCRIPTION D2 dopamine receptor antagonist; sigma receptor agonist; phenothiazine antipsychotic (LOPAC library)
DESCRIPTION Perphenazine is a typical antipsychotic drug, inhibits 5-HT2A receptor, Alpha-1A adrenergic receptor, Dopamine receptor D2/D3, D2L receptor, and Histamine H1 receptor. It is described as a typical antipsychotic and has been used extensively for schizophrenia and schizophrenia-like psychoses. (Enamine Bioactive Compounds)
DESCRIPTION Perphenazine (Trilafon) is a phenothiazine derivative and a dopamine antagonist with antiemetic and antipsychotic properties. (TargetMol Bioactive Compound Library)
DESCRIPTION Perphenazine dihydrochloride is an orally active dopamine receptor and histamine-1 receptor antagonist that acts on D2 (Ki: 0.56 nM), D3 (Ki: 0.43 nM), and 5-HT2A (Ki: 0.6 nM) receptors, and also binds Alpha-1A adrenergic receptors. It can induce apoptosis, inhibit cancer cell proliferation, and is used to study psychiatric disorders, cancer, and inflammation. (TargetMol Bioactive Compound Library)
Cell lines
9
Organisms
3
Compound Sets
36
Cayman Chemical Bioactives
20735
33298
ChEMBL Approved Drugs
CHEMBL567
ChEMBL Drugs
CHEMBL567
Concise Guide to Pharmacology 2017/18
209
Concise Guide to Pharmacology 2019/20
209
Concise Guide to Pharmacology 2021/22
209
Concise Guide to Pharmacology 2023/24
209
CZ-OPENSCREEN Bioactive Library
Drug Repurposing Hub
DrugBank
DB00850
DrugBank Approved Drugs
DB00850
DrugCentral
2113
DrugCentral Approved Drugs
2113
DrugMAP
DMA4MRX
DrugMAP Approved Drugs
DMA4MRX
DrugMatrix
Enamine Bioactive Compounds
EBC-00669
Enamine BioReference Compounds
EU-OPENSCREEN Bioactive Compound Library
EOS101436
EUbOPEN Chemogenomics Library
EUB0000788
Guide to Pharmacology
209
Ki Database
PERPHENAZINE
LOPAC library
LSP-MoA library (Laboratory of Systems Pharmacology)
CHEMBL567
Mcule NIBR MoA Box Subset
MCULE-6019566915
MedChem Express Bioactive Compound Library
HY-A0077
NCATS Inxight Approved Drugs
FTA7XXY4EZ
NIH Clinical Collections (NCC)
Novartis Chemogenetic Library (NIBR MoA Box)
NPC Screening Collection
Other bioactive compounds
Prestwick Chemical Library
ReFrame library
Selleckchem Bioactive Compound Library
perphenazine
TargetMol Bioactive Compound Library
T1090
T63115
The Spectrum Collection
External IDs
54
Properties
(calculated by RDKit )
Molecular Weight
403.15
Hydrogen Bond Acceptors
5
Hydrogen Bond Donors
1
Rotatable Bonds
6
Ring Count
4
Aromatic Ring Count
2
cLogP
3.94
TPSA
29.95
Fraction CSP3
0.43
Chiral centers
0.0
Largest ring
6.0
QED
0.79
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Selectivity
D2
Target
Dopamine Receptor
Histamine Receptor
Adrenergic Receptor
5-HT Receptor
CALM1, DRD1, DRD2, HRH1, HTR2A, HTR2C, HTR6, HTR7
Autophagy
D3
5-HT2A
CAM
dopamine
H1 receptor
α1A-adrenergic receptor
Pathway
GPCR/G protein
Neuronal Signaling
Immunology/Inflammation
Apoptosis
Neuroscience
Member status
virtual
MOA
Dopamine Receptor Antagonists
Dopamine Receptor antagonist
Indication
schizophrenia, nausea, vomiting
Disease Area
neurology/psychiatry, gastroenterology
Therapeutic Class
Antipsychotic Agents
Recommended Cell Concentration
10 nM
Source data